Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2012 |
| End Date: | January 2014 |
| Contact: | Karen Seiter, MD |
| Email: | karen_seiter@nymc.edu |
| Phone: | 914 493 7514 |
Phase II Trial of CLAG-M in Relapsed ALL
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the
agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will
determine the efficacy of the regimen in patients with relapsed ALL.
agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will
determine the efficacy of the regimen in patients with relapsed ALL.
Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone,
filgrastim). Standard support care will be given. Efficacy will be assessed through bone
marrow examinations and blood tests.
filgrastim). Standard support care will be given. Efficacy will be assessed through bone
marrow examinations and blood tests.
Inclusion Criteria:
- Relapsed or refractory acute lymphoblastic leukemia,
- Burkitts leukemia/lymphoma,
- Lymphoid blastic CML,
- Lymphoblastic lymphoma.
We found this trial at
1
site
Click here to add this to my saved trials
